anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system for generating a course of treatment (“COT”) recommender for recommending COTs for patients using machine learning is provided. A machine learning treatment recommendation (“MLTR”) system trains a COT recommender using training data that includes a feature vector and a label for each patient in a group of patients. The features of the feature vector may include features derived from patient data. A label is a course of treatment for a patient referred to as a labeling course of treatment. The MLTR system generates the training data from patient data collected over time. The MLTR system then uses the training data to train the COT recommender using a machine learning technique. Once the COT recommender has been trained, the COT recommender can be applied to a feature vector of patient data of a patient to generate an MLTR recommended course of treatment for the patient.
REBIF (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of REBIF is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (REBIF) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Using a reference standard calibrated against the World Health Organization natural interferon beta standard (Second International Standard for Interferon, Human Fibroblast GB 23 902 531), REBIF has a specific activity of approximately 270 million international units (MIU) of antiviral activity per mg of interferon beta-1a determined specifically by an in vitro cytopathic effect bioassay using WISH cells and Vesicular Stomatitis virus. REBIF 8.8 mcg, 22 mcg and 44 mcg contains approximately 2.4 million international units, 6 million international units or 12 million international units, respectively, of antiviral activity using this method.

REBIF (interferon beta-1a) is formulated as a sterile solution in a prefilled syringe or REBIF Rebidose autoinjector intended for subcutaneous (sc) injection. Each 0.5 mL (0.5 cc) of REBIF contains either 22 mcg or 44 mcg of interferon beta-1a, 2 mg or 4 mg albumin (human), 27.3 mg mannitol, 0.4 mg sodium acetate, and water for injection. Each 0.2 mL (0.2 cc) of REBIF contains 8.8 mcg of interferon beta-1a, 0.8 mg albumin (human), 10.9 mg mannitol, 0.16 mg sodium acetate, and water for injection.
The present invention discloses processing technology for Aconitum Carrnichaeli Debx, which relates to extraction technology for plant traditional Chinese medicine, particularly to extraction technology for Aconitum Carrnichaeli Debx of traditional Chinese medicine. The technology uses Aconitum Carrnichaeli Debx as a raw material. The Aconitum Carrnichaeli Debx is crushed, and water which is16 to 20 times the weight of the Aconitum Carrnichaeli Debx is added into the crushed Aconitum Carrnichaeli Debx. The crushed Aconitum Carrnichaeli Debx is decocted for 7 to 10 hours, and the crushed Aconitum Carrnichaeli Debx is filtered and concentrated. Ethanol is added into the crushed Aconitum Carrnichaeli Debx to be deposited, and extract in which the content of total alkaloid is from 4% to 7% and the content of diester alkaloid is from 0.23% to 0.6% is obtained. A medicament which is prepared by the technology can be directly applied to clinic, and can also be matched with other traditional Chinese medicine to be used. The content of the diester alkaloid in the medicament is low, and the content of the total alkaloid in the medicament is high. The clinical application of the present invention is safe. Microcirculation and platelet aggregation resistance can be markedly improved. The present invention can be used for treating the disease of a respiratory system, a cardiovascular system and a digestive system.
This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
PURPOSE:To conveniently obtain a substance soluble in an org. solvent in high yield by dipping a sample body contg. the substance to be extracted soluble in the org. solvent through a nonwoven fabric. CONSTITUTION:A sample body 1 contained in a nonwoven fabric 3 consisting of polypropylene, etc., and an org. solvent 2 are supplied into an extraction vessel 4. The amt. of the org. solvent is so regulated that the sample body 1 is sufficiently immersed. The extraction vessel 4 is heated by using a heater 5, cooling water is passed through a Dimroth condenser 6, hence the org. solvent in the extraction vessel 4 is refluxed and the substance to be extracted in the sample body 1 is extracted into the org. solvent. The substance dissolved in the org. solvent is permeated through the nonwoven fabric. The substance insoluble in the org. solvent is incapable of being permeated through the nonwoven fabric. Consequently, the substance in the sample body 1 soluble in the org.s solvent and the substance insoluble in the org. solvent are separated by the nonwoven fabric.
BACKGROUND: In 2015, the World Health Organization (WHO) introduced the concept of intrinsic capacity (IC) to define healthy aging based on functional capacity. In this scoping review, we summarized available evidence on the development and validation of IC index scores, the association of IC with health-related factors, and its biological basis. The review specifically focused on identifying current research gaps, proposed strategies to leverage biobank datasets, and opportunities to study the genetic mechanisms and gene-environment interactions underlying IC.
METHODS: The literature search was conducted across six databases, including PubMed, CINAHL, Web of Science, Scopus, AgeLine, and PsycINFO, using keywords related to IC.
RESULTS: This review included 84 articles, and most of them (n=38) adopted the 5-domains approach to operationalize IC, utilizing correlated five factors or bifactor structures. Intrinsic capacity has consistently shown significant associations with socio-demographic and health-related outcomes, including age, sex, wealth index, nutrition, exercise, smoking, alcohol use, ADL, IADL, frailty, multimorbidity, and mortality. While studies on the biological basis of the composite IC are limited, with only one study finding a significant association with the ApoE gene variants, studies on specific IC domains - locomotor, vitality, cognitive, psychological, and sensory suggest a heritability of 20-85% of IC and several genetic variants associated with these subdomains have been identified. However, evidence on how genetic and environmental factors influence IC is still lacking, with no available study to date.
CONCLUSION: Our review found that there was inconsistency in the use of standardized IC measurement tools and indicators, but the IC indices had shown good construct and predictive validity. Research into the genetic and gene-to-environment interactions underlying IC is still lacking, which calls for the use of resources from large biobank datasets in the future.
This will be a prospective collection of pre-defined parameters on the surgical treatment of male erectile dysfunction using Penile Prosthesis Implants (PPIs). The data collection will be undertaken from multiple centres in Europe. The participation will be by open invitation from the European Association of Urology (EAU) Section of Genitourinary Reconstructive Surgeons (ESGURS) to all its members, along with other urologists undertaking these procedures.

There will be no restriction on the number of patients enrolled per centre as long as they are consecutive. The aim is to have a long term collection of the dataset from as many centres as possible. An initial assessment for the robustness of the data collection and first clinical evaluation of the data collected will be performed 1 and 2 years after recruitment of the first patient by a nominated steering committee. Thereafter, the evaluations will be performed every 2 years until the end of Registry (10 years after the first patient was enrolled).
Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in the United States and is increasing in incidence; the prognosis remains dismal. We propose to investigate an entirely new approach, using pharmacological ascorbate, combined with Gemcitabine, to treat this cancer. Intravenous ascorbate (i.e., ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations, which are in the range that can be cytotoxic to tumor cells. Though ascorbate has been utilized in cancer therapy, few studies have investigated intravenous deliver of ascorbate. Preliminary studies from our group have demonstrated that ascorbate induces oxidative stress and cytotoxicity in pancreatic cancer cells; this cytotoxicity appears to be greater in tumor vs. normal cells. We hypothesize that production of H2O2 mediates the increased susceptibility of pancreatic cancer cells to ascorbate-induced metabolic oxidative stress. Gemcitabine is the standard chemotherapy drug used to treat pancreatic cancer.
A microporous catalyst contg. an activating agent selected from a biologically active agent, anion-blocking agent, or a dye is prepared from the preliminary soln. of a polymeric matrix dissolved in an organic solvent. The soln. is mixed with the activating agent to be a suspension, to which is added a polymer having a different molecular weight from that of the polymeric matrix, and with a polyfunctional reagent selected from aliphatic aldehyde, isocyanate, or thioisocyanate. Product is obtained by means of solidification, and extrusion or injection under dried conditions.
PROBLEM TO BE SOLVED: To obtain a cosmetic having light preventing effects, capable of effectively preventing especially UV light rays, by using both a specific triazine derivative and an emulsifying agent composed of a specific glyceryl compound. SOLUTION: 4,4',4"-(1,3,5-Triazine-2,4,6-triyltriimino)-trisbenzoic acid tris(2- ethylhexyl ester) of formula I is combined with an emulsifying agent composed of a glyceryl compound of formula II (R1 to R3 are each H or a 8-24C fatty acid; (n) is 2-8) and used. The added amount of the composed of formula I is fairly increased by adding the emulsifying agent of formula II. The amount of the compound of formula I added is 0.1-10.0wt.%, especially about 0.5-6.0wt.% based on the total of the composition. The amount of the compound of formula II added is 0.01-250.0wt.%, especially about 0.5-6.0wt.%. The composition is further mixed with 4-isopropylbenzyl salicylate, 2-ethylhexyl salicylate (octyl salicylate), etc., to give a composition further acting as a light protecting filter.
1388077 Modulating light NCR CORP 2 April 1973 [10 April 1972] 15673/73 Heading H4F [Also in Division C7] The molecules of a nematic liquid crystal phase are aligned parallel, and parallel to a substrate surface, by first vacuum depositing a layer of material on the substrate from a source disposed so that it does not lie on any line extending at 90 degrees from the substrate surface, and then placing the nematic material in contact with the layer. As described, any line connecting the substrate and source should make an angle with the surface normal of 10 to 89À9 degrees, and preferably about 80 degrees. The deposited layer is said to contain parallel oriented anisotropic growths which determine the direction of alignment of the nematic material. The deposited material may be of Pt, Au, Sn, Pb, Al, Cu, Ag, Cr or SiO and have a thickness of 20 Š upwards. The substrate may be electrically insulating, with or without an overlying electrode film, and the deposited layer may be sufficiently thin that it is non-continuous and so electrically non-conductive. Alternatively a thicker deposit on an insulating substrate may act as an electrode film. The layer may be deposited in a pattern for local remote alignment only. In both preferred embodiments, a nematic layer is sandwiched between two substrates having electrodes on their inner surfaces. The thin (non-conductive) layer deposited on one electrode has an alignment direction at 90 degrees to that of the other layer, whereby the cell is optically active in the absence of an electric field and appears isotropic to normally incident light when a field is applied. In a first ease, one electrode forms a selectively operable 7-segment display and the layer is deposited on both that electrode and the revealed substrate surface. In a second case both electrodes are continuous, and the layer on one electrode is deposited in a figure of eight pattern which is only visible between crossed polarizers when a potential difference is not applied between the electrodes.
Elevated lactate levels are a significant biomarker of sepsis and are positively associated with sepsis-related mortality. Sepsis-associated lung injury (ALI) is a leading cause of poor prognosis in clinical patients. However, the underlying mechanisms of lactate's involvement in sepsis-associated ALI remain unclear. In this study, we demonstrate that lactate regulates N6-methyladenosine (m6A) modification levels by facilitating p300-mediated H3K18la binding to the METTL3 promoter site. The METTL3-mediated m6A modification is enriched in ACSL4, and its mRNA stability is regulated through a YTHDC1-dependent pathway. Furthermore, short-term lactate stimulation upregulates ACSL4, which promotes mitochondria-associated ferroptosis. Inhibition of METTL3 through knockdown or targeted inhibition effectively suppresses septic hyper-lactate-induced ferroptosis in alveolar epithelial cells and mitigates lung injury in septic mice. Our findings suggest that lactate induces ferroptosis via the GPR81/H3K18la/METTL3/ACSL4 axis in alveolar epithelial cells during sepsis-associated ALI. These results reveal a histone lactylation-driven mechanism inducing ferroptosis through METTL3-mediated m6A modification. Targeting METTL3 represents a promising therapeutic strategy for patients with sepsis-associated ALI.
PURPOSE:To enhance the mechanical properties of a resin tooth and to prevent the discoloration thereof by respectively using materials composed of specific compositions in an enamel part and a dentine part and imperfectly polymerizing the dentin part and subsequently superposing the enamel part on said dentin part to perform perfect polymerization. CONSTITUTION:A compound consisting of a compound A having an ethylenic unsaturated double bond containing an urethane bond and a compound B having an ethylenic unsaturated double bond containing no urethane bond is used as the main component of a resin matrix and an inorg. or org. composite filler is added thereto and, further, a polymerization initiating catalyst and colorant are added thereto to constitute an enamel part. Furthermore, a filler, a polymerization initiating catalyst and a colorant are added to a component crosslinked by a compound, which consists of polymethyl methacrylate, methyl methacrylate, the compounds A, B, a compound C having an ethylenic unsaturated double bond containing a phenyl group and a compound D having an ethylenic unsaturated double bond containing an urethane bond and a phenyl group, to constitute a dentine part. The dentine part is previously polymerized imperfectly and the enamel part is superposed thereon to immediately perform perfect polymerization.
A total of 80 volunteers of patients underwent abdominal surgery will be recruited from the intensive care unit of China Medical University Hospital. After diagnosis by surgeon, these patients will be assigned to receive the conventional drug alone or the conventional drug combined electroacupuncture treatment. All participants receive intravenous injection the conventional drug, Metoclopramide, every 12 hours in the trial. Electroacupuncture, twice daily for three days, is administered 48-72 hours after abdominal surgery. Visual analogue scale, feeding volume, gastric residual volume and assessment of adverse events will be done for every visit. Laboratory biochemistry analysis and other assessments including Visual Analogue Scale, Acute Physiology and Chronic Health Evaluation II score, and Sequential Organ Failure Assessment score will be completed at baseline and the end of intervention(3 days after initation of the intervention). Physiological and operative severity scores for the enumeration of mortality and morbidity (POSSUM) score will be done at the baseline. Instrumental examinations including heart rate variability and traditional Chinese medicine four examinations will be given before and after intervention. We expect that the efficacy of combined electroacupuncture with conventional drug is superior to conventional drug only in alleviation of gastrointestinal distension or/and improvement of motility in patients who underwent abdominal surgery. Moreover, we will further speculate the mechanism by analyzing laboratory data.
In the Group (DA), the standard consisting of electrocardiogram(ECG), peripheral oxygen saturation (Spo2), and non-invasive blood pressure will be monitored.Prior to induction, the first blood sample (To) will be taken for analysis. After induction of anesthesia with propofol and rocuronium, he will be intubated.Anesthesia will be maintained with desflurane (MAC:1), oxygen (50%), air (50%). After a high flow phase of 4 l/min for 10 min, the fresh gas flow will be reduced to 0.6 L/min and fentanyl,rocuronium will be administered intermittently. Patients will be ventilated with a ventilator at a constant tidal volume (kg x 6 mL) and respiratory rate (12/min). At the 1st hour of low flow anesthesia maintenance, a second blood sample (T1) will be taken for analysis. Patients will be awakened at the end of the case. After the recovery room, it will be transferred to the relevant service. A third blood sample (T2) will be taken at the postoperative 24th hour in the service for analysis.
The present invention relates to the fields of biology and pharmacology. This invention relates, generally, to methods and compositions for modulating oxLDL activity or transport. The present invention resides more specifically in methods for screening compounds that modulate oxLDL activity, more particularly oxLDL cellular uptake. The present invention more particularly describes novel methods of selecting or identifying compounds that can modulate oxLDL cellular binding, uptake and/or degradation by CD36 polypeptides and especially CD36 polypeptides comprising a functional cytoplasmic domain in various cells, such as macrophages. The invention also relates to the use of such compounds, in particular for research, development, improvement, diagnosis, therapeutic or prohylactic treatment of various pathological conditions. The invention also relates to the products or compositions, such as CD36 variants, recombinant cells, vectors, kits, and the like, which can be used for implementing the above methods or for therapeutic purposes.
The invention provides high concentration pidotimod oral liquid, which can promote human body immune response, effectively reduces times and degree of acute attack of infections caused by bacteria or virus, shortens disease course, can serve as auxiliary medicine antibiotic of acute infection and belongs to the field of medicines. The oral liquid contains constitutions of pidotimod, chemical stabilizer, a potential of hydrogen (pH) adjusting agent, a flavoring agent and the like.  Tris-(hydroxymethyl)-aminomethane is used as the pH adjusting agent. The oral liquid is stable in quality and convenient to store for a long time. By means of quantitative proportioning and synergistic effect of all constitutions, when the concentration of the oral liquid is improved, simultaneously the stability and taste of the oral liquid are obviously improved. The oral liquid doesn't contain sugar capable of being absorbed and used by human bodies and is suitable for the old and children.
The universe of the study consisted of preterm newborns patients who met the selection criteria in newborn intensive care unit.The research was planned as a randomized controlled experimental study. In order for the groups to be distributed homogeneously, the order produced by a computer program (http://www.randomizer.org/) was used. Patients who meet the inclusion criteria and agree to participate in the study assigned to the experimental and control groups according the randomization list. The control variable of the study is demographic characteristics of the baby. The dependent variables of the study are physiological parameters, newborn position assesment tool score and newborn stress scale score In the research, "Information and follow-up form" prepared by the researcher in line with the literature was used as data collection tools. Newborn Position Assesment Tool and Newborn Stress Scale were also used
Patient: Adult glioma, pathological diagnosis combined with molecular diagnosis (i.e. IDH- mutant glioma, IDH- mutant glioma with 1p/19q- co-deletion, glioblastoma). The patients were divided into three groups: group A (IDH mutant glioma), group B (IDH mutant with 1p/19q co-deletion oligodendroglioma ) and group C (IDH wild glioblastoma). From the first day after surgery, the ctDNA was extracted with TISF before concurrent chemoradiotherapy as the baseline, and the ctDNA was detected again after concurrent chemoradiotherapy. For the third time, ctDNA was detected in temozolomide intensive chemotherapy. ctDNA was detected for the fourth time when the image showed tumor progression. After the progress, temozolomide combined with bevacizumab was used for chemotherapy. ctDNA was detected 6 weeks after the application of bevacizumab, and ctDNA was re-measured every 6 weeks during the treatment of bevacizumab. At the same time, imaging examination was performed to determine the tumor progress. Check and record adverse events and drug use in detail, and evaluate the compliance of subjects; After TISF tissue extraction, the retained blood samples were sent to simcere Company and Beijing Genetron Health Technology Co. Ltd for ctDNA quantification and detection. To study the differences of gene evolution of different subtypes of glioma under pressure therapy, to clarify the differences of molecular responses of different subtypes of glioma to bevacizumab, and to evaluate the therapeutic effect and safety.
To provide satellite cells and compositions and methods for producing the same.SOLUTION: Disclosed herein are methods for producing satellite cells and compositions including satellite cells. In one aspect, the disclosure provides a non-naturally occurring satellite cell. In another aspect, the non-naturally occurring satellite cell exhibits a morphology that resembles the morphology of an endogenous satellite cell. In another aspect, the non-naturally occurring satellite cell expresses Pax7. In another aspect, the non-naturally occurring cell exhibits a response to a muscle injury. In another aspect, the non-naturally occurring satellite cell initiates muscle regeneration following transplantation.SELECTED DRAWING: None
Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.